Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
| Revenue (TTM) | $160.03M |
| Gross Profit (TTM) | $61.33M |
| EBITDA | $-143.15M |
| Operating Margin | -102.90% |
| Return on Equity | -273.60% |
| Return on Assets | -12.00% |
| Revenue/Share (TTM) | $0.53 |
| Book Value | $0.01 |
| Price-to-Book | 179.19 |
| Price-to-Sales (TTM) | 2.70 |
| EV/Revenue | 5.32 |
| EV/EBITDA | 140.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.10% |
| Shares Outstanding | $310.60M |
| Float | $303.83M |
| % Insiders | 8.77% |
| % Institutions | 53.78% |
Volatility is currently contracting
MENLO PARK, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 9:00 AM ET in Boston, Massachusetts.
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.36, indicating a -5.56% shift from the previous trading day.
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.66, moving 1.19% from the previous trading session.
Pacific Biosciences of California (PACB) closed at $1.68 in the latest trading session, marking a -2.89% move from the prior day.
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PACB and any ticker you trade — then tracks every position and per-strategy win rate.
